Eric Coldwell
Stock Analyst at Baird
(3.93)
# 607
Out of 5,090 analysts
182
Total ratings
62.04%
Success rate
6.72%
Average return
Main Sectors:
Stocks Rated by Eric Coldwell
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MCK McKesson | Maintains: Outperform | $873 → $927 | $808.62 | +14.64% | 18 | Nov 6, 2025 | |
| CRL Charles River Laboratories International | Upgrades: Outperform | $178 → $199 | $184.31 | +7.97% | 15 | Nov 6, 2025 | |
| IQV IQVIA Holdings | Upgrades: Outperform | $224 → $258 | $225.85 | +14.24% | 19 | Oct 29, 2025 | |
| FTRE Fortrea Holdings | Maintains: Outperform | $9 → $14 | $14.24 | -1.69% | 9 | Sep 3, 2025 | |
| ICLR ICON Public Limited Company | Maintains: Outperform | $222 → $224 | $185.80 | +20.56% | 22 | Sep 2, 2025 | |
| DGX Quest Diagnostics | Downgrades: Neutral | $194 | $182.51 | +6.30% | 11 | Aug 25, 2025 | |
| CAH Cardinal Health | Maintains: Outperform | $197 → $203 | $198.83 | +2.10% | 13 | Aug 13, 2025 | |
| OMI Owens & Minor | Maintains: Outperform | $10 → $7 | $2.59 | +170.27% | 19 | Aug 12, 2025 | |
| LH Labcorp Holdings | Maintains: Outperform | $290 → $302 | $258.39 | +16.88% | 14 | Jul 25, 2025 | |
| MEDP Medpace Holdings | Maintains: Neutral | $313 → $490 | $548.12 | -10.60% | 19 | Jul 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $14 → $16 | $9.42 | +69.85% | 10 | Feb 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $35 → $45 | $58.15 | -22.61% | 2 | Jun 26, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $62 → $66 | $75.63 | -12.73% | 7 | May 7, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $67 → $46 | $1.36 | +3,282.35% | 4 | Nov 10, 2017 |
McKesson
Nov 6, 2025
Maintains: Outperform
Price Target: $873 → $927
Current: $808.62
Upside: +14.64%
Charles River Laboratories International
Nov 6, 2025
Upgrades: Outperform
Price Target: $178 → $199
Current: $184.31
Upside: +7.97%
IQVIA Holdings
Oct 29, 2025
Upgrades: Outperform
Price Target: $224 → $258
Current: $225.85
Upside: +14.24%
Fortrea Holdings
Sep 3, 2025
Maintains: Outperform
Price Target: $9 → $14
Current: $14.24
Upside: -1.69%
ICON Public Limited Company
Sep 2, 2025
Maintains: Outperform
Price Target: $222 → $224
Current: $185.80
Upside: +20.56%
Quest Diagnostics
Aug 25, 2025
Downgrades: Neutral
Price Target: $194
Current: $182.51
Upside: +6.30%
Cardinal Health
Aug 13, 2025
Maintains: Outperform
Price Target: $197 → $203
Current: $198.83
Upside: +2.10%
Owens & Minor
Aug 12, 2025
Maintains: Outperform
Price Target: $10 → $7
Current: $2.59
Upside: +170.27%
Labcorp Holdings
Jul 25, 2025
Maintains: Outperform
Price Target: $290 → $302
Current: $258.39
Upside: +16.88%
Medpace Holdings
Jul 23, 2025
Maintains: Neutral
Price Target: $313 → $490
Current: $548.12
Upside: -10.60%
Feb 27, 2025
Maintains: Outperform
Price Target: $14 → $16
Current: $9.42
Upside: +69.85%
Jun 26, 2020
Maintains: Neutral
Price Target: $35 → $45
Current: $58.15
Upside: -22.61%
May 7, 2020
Maintains: Neutral
Price Target: $62 → $66
Current: $75.63
Upside: -12.73%
Nov 10, 2017
Maintains: Outperform
Price Target: $67 → $46
Current: $1.36
Upside: +3,282.35%